[{"orgOrder":0,"company":"TikkunLev Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"TLT-101","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"TikkunLev Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"TikkunLev Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"TikkunLev Therapeutics \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by TikkunLev Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          RNA Therapeutics
                          Not Confirmed
                          RNA Therapeutics
                          Not Confirmed

                          Details : The proceeds from the seed financing will support ongoing clinical development of TLT-101 for multiple serious forms of heart failure, with an initial focus on non-ischemic dilated cardiomyopathy.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 29, 2024

                          Lead Product(s) : TLT-101

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank